Northrop Grumman's B-21 Boost, Stock Drop

0:00Northrop Grumman just dropped their first quarter 2026 earnings, and by all accounts, it was a solid report. Sales hit $9.9 billion, up 4% from last year, with earnings per share at $6.14, beating. Expectations abid. They reaffirmed full-year guidance for sales around $43.5 to $44 billion, and free cash flow between $3.1. And $3.5 billion plus a massive $96 billion backlog. But here's the twist that tanked the stock. They're ramping up production on the B-21 Stealth Bomber by about 25% in lockstep, with the Air Force. That means higher capital spending, with 2026 CAPEX, now at $1.85 billion, up 200 million from before, and a total $2.5 billion investment through 2029. Investors got spooked by the near-term cash flow pressure, even though full-year free cash flow guidance didn't budge.

1:01It's that classic Wall Street head scratcher, where good news gets buried under one big number, leaving retail folks scratching their heads while. Shares dipped. Morgan Stanley trimmed their price target to $745 from $765, but they're calling this sell-off. A straight-up buying opportunity. Their models show free cash flow dipping a touch in 2026 to about $3.28 billion, then climbing to $3. $4 billion in 2027, $3.64 billion in 2028, and $4.16 billion in 2029. This all highlights Northrop's prime spot in rising defense budgets, from the B-21 to nuclear triad programs and potential wins like the F. Slash A, dash XXX fighter contract coming up in August. Smart money's betting the medium-term payoff outweighs today's pinch. That's your update from Durham News Today, powered by AI.